Back to Results

BioNexus Gene Lab Corp (BGLC)

BioNexus Gene Lab Corp is a Malaysia-based company incorporated in 2017 and listed on NASDAQ as common stock under the ticker BGLC. Through its subsidiaries, the company operates in Southeast Asia, including Malaysia, Indonesia, Vietnam, and other regional markets. Its business is organized into three segments: trading of industrial chemicals, genomic screening services, and investment holding. The trading activity focuses on chemical raw materials used in the manufacture of industrial, medical, appliance, automotive, aero, mechanical, and electronic products. The company also develops and provides non-invasive liquid biopsy tests designed for early biomarker detection.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-BGLC
$2.36
44.7% Upside
Undervalued
—
—
—
Weak
—
—
—
0.0%
August 14, 2026
-1.4x
0.5x
0.7x
4.037 M
321.883 K
7.9%
72.7%
10.6
—
41.0%
Send a message
Valuation • Fair Value

BioNexus Gene Lab Corp (NASDAQ-BGLC) Fair Value by Valuation Model

Compare the primary fair value estimate for BioNexus Gene Lab Corp (NASDAQ-BGLC) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.36

Estimated upside of 44.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$2.36

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for BioNexus Gene Lab Corp (NASDAQ-BGLC) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for BioNexus Gene Lab Corp (NASDAQ-BGLC)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

5.311 M

Current operating scale indicator.

Revenue Forecast

7.425 M

Forward revenue estimate.

EBITDA

-2.962 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review BioNexus Gene Lab Corp (NASDAQ-BGLC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for BioNexus Gene Lab Corp (NASDAQ-BGLC)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-4.34

No elevated caution signal from this screen.

Altman Z-Score

10.6

Relatively strong balance-sheet zone.

FCF / Net Income

41.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for BioNexus Gene Lab Corp (NASDAQ-BGLC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for BioNexus Gene Lab Corp (NASDAQ-BGLC)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 14, 2026

Days to Earnings

24

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for BioNexus Gene Lab Corp (NASDAQ-BGLC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

BioNexus Gene Lab Corp (NASDAQ-BGLC) Stock Forecast & Technical Outlook

Review BioNexus Gene Lab Corp (NASDAQ-BGLC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for BioNexus Gene Lab Corp (NASDAQ-BGLC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for BioNexus Gene Lab Corp (NASDAQ-BGLC) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

BioNexus Gene Lab Corp (NASDAQ-BGLC) Stock FAQ

Quick answers about BioNexus Gene Lab Corp (NASDAQ-BGLC) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.36
Estimated upside 44.7%
Valuation Rating
Undervalued
Estimated upside of 44.7%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for BioNexus Gene Lab Corp (NASDAQ-BGLC) is $2.36. This implies an estimated upside of 44.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 44.7% versus the current market price.

An analyst price target for BioNexus Gene Lab Corp (NASDAQ-BGLC) is not currently available in the latest data file.

The current financial health read for BioNexus Gene Lab Corp (NASDAQ-BGLC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for BioNexus Gene Lab Corp (NASDAQ-BGLC) is August 14, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for BioNexus Gene Lab Corp (NASDAQ-BGLC) is -1.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for BioNexus Gene Lab Corp is 4.037 M.

The current enterprise value listed for BioNexus Gene Lab Corp is 321.883 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for BioNexus Gene Lab Corp is NASDAQ-BGLC, and the stock is listed on NASDAQ.

BioNexus Gene Lab Corp (NASDAQ-BGLC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for BioNexus Gene Lab Corp is 7.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for BioNexus Gene Lab Corp is 72.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Trading Companies & Distributors Stocks on NASDAQ View more

Fastenal Company (FAST) Fastenal Company (FAST)
Rush Enterprises A Inc (RUSHA) Rush Enterprises A Inc (RUSHA)
Rush Enterprises B Inc (RUSHB) Rush Enterprises B Inc (RUSHB)
Xometry Inc (XMTR) Xometry Inc (XMTR)
EquipmentShare Com Inc (EQPT) EquipmentShare Com Inc (EQPT)
McGrath RentCorp (MGRC) McGrath RentCorp (MGRC)
DXP Enterprises Inc (DXPE) DXP Enterprises Inc (DXPE)
Distribution Solutions Group Inc (DSGR) Distribution Solutions Group Inc (DSGR)
Willis Lease Finance Corporation (WLFC) Willis Lease Finance Corporation (WLFC)
Transcat Inc (TRNS) Transcat Inc (TRNS)
Karat Packaging Inc (KRT) Karat Packaging Inc (KRT)
Titan Machinery Inc (TITN) Titan Machinery Inc (TITN)
Hudson Technologies Inc (HDSN) Hudson Technologies Inc (HDSN)
Texxon Holding Ltd (NPT) Texxon Holding Ltd (NPT)
Simpple Ltd (SPPL) Simpple Ltd (SPPL)
Marwynn Holdings Inc (MWYN) Marwynn Holdings Inc (MWYN)
Ten League International Hold Ltd (TLIH) Ten League International Hold Ltd (TLIH)
Euro Tech Holdings Company Ltd (CLWT) Euro Tech Holdings Company Ltd (CLWT)
FGI Industries Ltd (FGI) FGI Industries Ltd (FGI)
Capstone Holding Corp (CAPS) Capstone Holding Corp (CAPS)
IPower Inc (IPW) IPower Inc (IPW)